A two stage PCR-SSOP typing procedure, that permitted HLA-B allele assignment, was applied to DNA samples obtained from six diverse populations -Brazilian, Mexican (Series and Mestizos), Cuban (Caucasoid and Mulatto), South African Zulu, Omani, and Singapore Chinese. HLA-B allele frequencies and HLA-A/B two locus haplotype frequencies were compiled for each population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0198-8859(01)00247-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Significance of HLA-B*15 in three pemphigus patients with rituximab-triggered severe cutaneous drug reactions.
Postepy Dermatol Alergol
December 2024
Department of Dermatology and Venerology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Introduction: Rituximab, a CD20 inhibitor, has swiftly become the primary treatment for pemphigus patients.
Aim: We present 3 cases of pemphigus patients who had undergone rituximab treatment.
Material And Methods: After the second intravenous administration of rituximab, the primary rash developed into severe cutaneous drug reactions.
Influence of HLA-B Leader (-21M/T) Dimorphism With Bw4/Bw6 Epitopes on Graft Versus Host Disease After Allogenic Haematopoietic Stem Cell Transplantation in North Indians.
Int J Immunogenet
January 2025
Department of Clinical Haematology and Medical Oncology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
High degree of variability in human leukocyte antigens (HLAs) system restricts availability of histocompatible HLA-matched-related donors, thus increasing reliance on worldwide bone marrow registries network. Nevertheless, due to limited coverage/accessibility/affordability of some ethnicities in these registries, haploidentical haematopoietic stem cell transplantation (HSCT) emerged as an alternative option, though with allorecognition-mediated graft versus host disease (GvHD) (>40% cases). A dimorphism [-21 methionine (M) or threonine (T)] in HLA-B leader peptide (exon 1) which differentially influences its HLA-E binding, plausibly regulates natural killer cell functionality, affecting GvHD vulnerability and clinically in practice for donor selection.
View Article and Find Full Text PDFIdentification of the Novel HLA-B*15:245:02Q Allele in a Chinese Individual.
HLA
January 2025
Department of Transfusion Research, Wuhan Blood Center, Wuhan, China.
HLA-B*15:245:02Q differs from HLA-B*15:01:01:01 by two nonsynonymous nucleotides exchanges in exon 3.
View Article and Find Full Text PDFThe New HLA-B*44:384 Allele Characterised by Two Different Sequencing-Based Typing Techniques.
HLA
January 2025
HLA and Histocompatibility Laboratory, CHRU de Nancy, Vandœuvre-lès-Nancy, France.
The new allele HLA-B*44:384 differs from HLA-B*44:02:01:01 by one non-synonymous nucleotide substitution in exon 2.
View Article and Find Full Text PDFThe Novel HLA-B*37:114 Allele Identified by Next-Generation Sequencing in a Chinese Individual.
HLA
January 2025
Department of Transfusion, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
HLA-B*37:114 has a single non-synonymous change from HLA-B*37:01:01:01 changing residue 163 from Threonine to Lysine'.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!